Overview
Clinical stage TechBio firm's Q4 operating revenue beat analyst expectations
Net income for Q4 exceeded analyst estimates
Company achieved milestone payment from Sanofi, totaling $134 mln to date
Outlook
Recursion expects cash runway to extend into early 2028 without additional financing
Company anticipates milestone payments as Sanofi programs advance in next 12-18 months
Recursion plans FDA engagement for REC-4881 in 1H26 to discuss registration pathway
Result Drivers
AI OPERATING SYSTEM VALIDATION - Recursion achieved first clinical validation of its AI Operating System in FAP, demonstrating translation from AI-driven biological insight to patient outcomes
SANOFI MILESTONE PAYMENTS - Recursion received $134 mln in milestone payments from Sanofi, reflecting progress in AI-driven small molecule programs
COST MANAGEMENT - Exceeded original cost savings guidance, extending cash runway into early 2028 without additional financing
Company press release: ID:nGNX6FGL8n
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Operating Revenue | Beat | $35.35 mln | $24.59 mln (7 Analysts) |
Q4 Net Income | Beat | -$108.12 mln | -$131.06 mln (5 Analysts) |
Q4 Pretax Profit | Beat | -$108.10 mln | -$113.87 mln (3 Analysts) |
Q4 Operating Income | -$108.34 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $7.00, about 98.3% above its February 24 closing price of $3.53
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)